Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis
@article{TLCR85530, author = {Gengwei Huo and Ying Song and Xiongwen Chen and Peng Chen}, title = {Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis}, journal = {Translational Lung Cancer Research}, volume = {13}, number = {4}, year = {2024}, keywords = {}, abstract = {}, issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/85530} }